Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Biopharma stocks go back to bleak
Hopes for a better 2023 look optimistic as markets take another turn for the worse.
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Protagonist “delighted” with trial failure
Development of the ulcerative colitis project PN-943 continues.
Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.